In a major strategic move to counter shifting U.S. trade policies, Amgen ($AMGN) has just announced an additional $300 million investment in its Puerto Rico manufacturing site.
This isn’t just about growth—it’s a survival masterplan in a new era of protectionism.
🚀 The Catalyst: Why Amgen is Doubling Down on U.S. Soil
The decision stems from a new executive order imposing tariffs of up to 100% on imported branded medicines. To protect margins and secure their supply chain, Big Pharma giants now face a clear choice:
- Commit to government drug-pricing deals.
- Or commit to domestic manufacturing (Onshoring).
Amgen is choosing the latter, aggressively expanding its U.S. footprint to shield itself from the 2026 “Tariff Shock.”
📍 Amgen’s Billion-Dollar U.S. Investment Roadmap (2025-2026):
🔹 Puerto Rico (Juncos): Total investment has now reached $950 million. This facility is a global biologics powerhouse, distributing medicines to over 60 countries and creating 750 new jobs. 🔹 Ohio: $900 million dedicated to a new biomanufacturing plant focused on advanced assembly and packaging. 🔹 North Carolina: A record-breaking $1.5 billion+ investment for a long-term therapeutic protein manufacturing hub. 🔹 California: $600 million for a state-of-the-art Science and Innovation Center at their Thousand Oaks headquarters.
💡 Strategic Vision for 2026 and Beyond:
By leveraging the recent extensions of the Tax Cuts and Jobs Act (TCJA), Amgen is turning a massive regulatory challenge into a modernization opportunity.
However, this is also a race against the clock. With current tax incentives and tariff exemptions potentially shifting by 2029, Amgen is betting that building a world-class domestic infrastructure now will provide the ultimate leverage for any future policy landscape.
#Amgen #Pharma #Manufacturing #PuertoRico #Tariffs #Investing #SupplyChain #Biotech #TrumpTariffs #MacroEconomics #FinanceNews #AMGN #Onshoring